Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.
Saved in:
| Title: | Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer. |
|---|---|
| Authors: | As Sobeai HM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Alanazi AM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia., Alotaibi F; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Inpatient Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia., Alhoshani A; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Alhazzani K; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almutairi MM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almudimeegh S; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Al-Ramadi BK; Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates., Chakraborty E; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States., Saleh T; Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain.; Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, Jordan., Gewirtz DA; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States., Harada H; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.; School of Dentistry, Philips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, VA, United States., Alotaibi MR; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. |
| Source: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2026 Feb 05; Vol. 14, pp. 1661424. Date of Electronic Publication: 2026 Feb 05 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2026.1661424 |
